Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Publication date

2025-09-15

Authors

Stockem, Chantal F
Gil-Jimenez, Alberto
Ali, Hamza
van Dorp, Jeroen
van Dijk, Nick
van Montfoort, Maurits L
Alkemade, Maartje
Broeks, Annegien
Seignette, Iris M
Hooijberg, Erik

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

taverne

Abstract

PURPOSE: In NABUCCO, the safety and efficacy of preoperative ipilimumab plus nivolumab were assessed in stage III urothelial cancer. Encouraging responses were achieved, and ipilimumab 3 mg/kg (ipilimumab-high) seemed more effective than ipilimumab 1 mg/kg (ipilimumab-low). We explored ipilimumab plus nivolumab response biomarkers and tumor microenvironment (TME) treatment dynamics. PATIENTS AND METHODS: Baseline formalin-fixed, paraffin-embedded tumor tissue was analyzed using PD-L1 IHC (n = 51) and whole-exome and transcriptome sequencing (both n = 53) and correlated with response. Baseline infiltration of CD8+ T cells (n = 51) and at cystectomy (n = 42) was examined. Single-cell RNA sequencing (scRNA-seq) of CD3+ T cells was conducted on on-treatment resection tissue of two responders to ipilimumab-high to explore the characteristics of CD8+ T cells within the TME. RESULTS: High tumor mutational burden and PD-L1 positivity were associated with response to ipilimumab plus nivolumab. Nonresponding patients exhibited increased expression of a TGFβ signature. We observed increased transcription of the g2m checkpoint and e2f target in responders to ipilimumab-high and enhanced transcription of IFN-α and IFN-γ hallmarks in responders to ipilimumab-low. CD8+TCF7+ T cells accumulated in the TME of responders to ipilimumab-high. scRNA-seq of CD8A+TCF7+ T cells demonstrated enhanced expression of IL7R, CCR7, GPR15, XCL1, SELL, and LEF1. CONCLUSIONS: Our data indicate that tumor mutational burden, PD-L1, and TGFβ are potential biomarkers for response to ipilimumab plus nivolumab in stage III urothelial cancer. An inflammatory TME might be relevant for responding to ipilimumab-low. We found that in responders to ipilimumab-high, TCF7+CD8+ T cells accumulated in the TME. scRNA-seq in two responders suggested that TCF7+CD8A+ T cells express genes associated with immunologic memory formation and T-cell homing.

Keywords

Taverne, Journal Article

Citation

Stockem, C F, Gil-Jimenez, A, Ali, H, van Dorp, J, van Dijk, N, van Montfoort, M L, Alkemade, M, Broeks, A, Seignette, I M, Hooijberg, E, Brugman, W, Voogd, R, van Rhijn, B W G, Mertens, L S, Feijter, J M D, Mehra, N, van der Heijden, A G, Meijer, R P, Suelmann, B B M, Scheper, W, Wessels, L F A, Vis, D J & van der Heijden, M S 2025, 'Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 31, no. 18, pp. 3897-3906. https://doi.org/10.1158/1078-0432.CCR-25-0419